At a glance
ClinicalIndex Comparison RecordN/ACompleted· 561 enrolled
Drug / intervention
Daivobet® Geldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation
In Brief
An observational study evaluating Daivobet® Gel for Psoriasis Vulgaris and Plaque Psoriasis. Completed, enrolled 561 participants across 1 site.
Detailed Summary
The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris, Plaque Psoriasis
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionMay 2014
Study CompletionJul 2014
TodayJul 2026
First PostedOct 16, 2012
Enrollment StartOct 1, 2012
Primary CompletionMay 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.7 years ago
Interventions
Daivobet® Geldrug
Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.